TetraGenx acquired by Tropichem Research Labs in cross-border transaction

21 March 2018

On March 21, 2018, Tropichem Research Labs, LLC acquired TetraGenx Inc.

Tropichem is a portfolio company of St. Louis-based private equity firm Thompson Street Capital Partners. Tropichem develops, manufactures and packages animal care, personal care and household and industrial products out of its facility in Florida.

Montreal-based TetraGenx is a leading independent animal health contract development and manufacturing organization. TetraGenx specializes in complex drug product formulation development to create innovative pharmaceutical, over-the-counter and nutraceutical veterinary pharma products. Its services encompass four main categories, including product development, analytical testing, manufacturing and ancillary support services.

Gowling WLG was counsel to the selling shareholders of TetraGenx Inc. and related entities with a team led by Jean-François Pelland that included, among others, Peter Fairey, Georgi Paskalev and Jordana Levine (corporate/M&A); Laura Gheorghiu, Daniel Lacelle and Brent Kerr (tax); with the assistance of paralegals Monique Talbot and Silvana Pella.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.